Head-to-head evidence
Anhui HygeianCells EE001 vs HiCM-188 (allogeneic iPSC-cardiomyocytes)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Heart Failure
Shared mechanism: Cardiac cell therapy · full Heart Failure pipeline
Anhui HygeianCells EE001
Developed by Anhui HygeianCells BioMedical
NCT06884111 · Phase 1 · completed
Only 6 people received the drug, all in a single open, unblinded group with no placebo or comparison arm, so any change seen cannot be attributed to the drug with confidence. No results have been posted yet.
HiCM-188 (allogeneic iPSC-cardiomyocytes)
Developed by HELP Therapeutics
NCT03763136 · Phase 1/2 · completed
The trial randomized 20 participants to hPSC-CM therapy or a sham comparator consisting of coronary artery bypass surgery alone, with outcome assessors masked to treatment assignment. Its primary endpoints were clinical safety outcomes, but results are not posted and the small sample limits the strength of the evidence.
Next expected readout: November 2026 · NCT06340048 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Anhui HygeianCells EE001's landscape · HiCM-188 (allogeneic iPSC-cardiomyocytes)'s landscape